OrexiCAR T / CoImmune, Memorial Sloan-Kettering Cancer Center - LARVOL DELTA

CoImmune Announces Novel Engineered CAR T Cells Improve Anti-Tumor Activity and Reverse Immunosuppression in Preclinical Models (PRNewswire) - "CoImmune, Inc...announced that preclinical models show CAR T cells engineered with OrexiCAR technology to secrete a CD47-SIRPα checkpoint blocker have improved anti-tumor activity and reverse myeloid immunosuppression in tumors....Results demonstrate that OrexiCAR T cells plus rituximab were additive in effect on lymphoma tumor regressions and mouse survival without new toxicities: 80 percent of mice treated with OrexiCAR T cells had no detectable tumor at day 86 post tumor engraftment, as compared to only 25 percent treated with wild type CAR T cells, in conjunction with rituximab; Mice treated with OrexiCAR T cells had significantly improved median overall survival compared to those treated with wild type CAR T cells in combination with rituximab or CV1 plus rituximab."

Preclinical • Oncology